Published in Nat Med on June 01, 1997
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates. J Exp Med (2010) 1.63
Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med (2013) 1.59
Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. J Virol (1999) 1.37
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology (2008) 1.26
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J Virol (1998) 1.21
beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci U S A (1998) 1.20
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J Virol (1998) 1.19
Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine (2011) 1.16
INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther (2009) 1.08
Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine (2007) 1.04
Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther (2008) 1.01
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00
Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol (2012) 0.99
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol (2010) 0.98
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol (2010) 0.93
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials. Viruses (2010) 0.86
Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther (2010) 0.85
Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc Natl Acad Sci U S A (2005) 0.84
Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein. PLoS One (2012) 0.84
Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines. J Virol (2014) 0.84
Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses. Clin Immunol (2014) 0.83
HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology (2014) 0.83
Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses. PLoS One (2012) 0.83
Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One (2013) 0.83
Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine (2011) 0.81
Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys. J Virol (2013) 0.81
Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. Clin Exp Immunol (2001) 0.80
Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques. Clin Immunol (2014) 0.80
Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine (2010) 0.80
Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis. Clin Vaccine Immunol (2012) 0.80
Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy. Virology (2015) 0.79
Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. PLoS One (2015) 0.79
Identification of a suppressor mutation that improves the yields of hexon-modified adenovirus vectors. J Virol (2013) 0.77
Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS. J Virol (2013) 0.77
Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. PLoS One (2016) 0.75
AIDS vaccine development: let a thousand flowers bloom. J Clin Pathol (1998) 0.75
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 32.33
Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A (1980) 30.08
RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature (1970) 19.89
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science (1995) 17.42
The role of mononuclear phagocytes in HTLV-III/LAV infection. Science (1986) 17.33
Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science (2009) 13.45
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. Nature (1977) 12.57
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 11.30
Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A (1982) 11.15
Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature (1999) 10.97
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A (1985) 10.71
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome. Science (1984) 10.40
Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci U S A (1978) 9.59
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
A molecular clone of HTLV-III with biological activity. Nature (1985) 8.30
Isolation of a new virus, HBLV, in patients with lymphoproliferative disorders. Science (1986) 8.15
Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization. Proc Natl Acad Sci U S A (1986) 8.06
Complete nucleotide sequences of functional clones of the AIDS virus. AIDS Res Hum Retroviruses (1987) 7.85
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature (1982) 6.78
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science (1986) 6.53
Trans-acting transcriptional regulation of human T-cell leukemia virus type III long terminal repeat. Science (1985) 6.51
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science (1992) 6.35
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Functional and morphologic characterization of human T cells continuously grown in vitro. J Immunol (1977) 6.30
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol (1987) 6.20
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol (1988) 5.96
Sequence of retrovirus provirus resembles that of bacterial transposable elements. Nature (1980) 5.95
Long-term cultures of HTLV-III--infected T cells: a model of cytopathology of T-cell depletion in AIDS. Science (1986) 5.86
Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 5.80
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibody. Proc Natl Acad Sci U S A (1986) 5.55
The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection. Nat Med (1996) 5.46
Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J Virol (1990) 5.45
Serological analysis of a subgroup of human T-lymphotropic retroviruses (HTLV-III) associated with AIDS. Science (1984) 5.43
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Genomic diversity of human T-lymphotropic virus type III (HTLV-III). Science (1985) 5.33
A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science (1982) 5.30
Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature (1982) 5.11
Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci U S A (1985) 5.10
HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature (1985) 5.10
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
Human T-lymphotropic retroviruses. Nature (1985) 5.04
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A (1980) 4.91
Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci U S A (1984) 4.90
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A (1997) 4.89
Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature (1983) 4.83
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Cloning and characterization of different human sequences related to the onc gene (v-myc) of avian myelocytomatosis virus (MC29). Proc Natl Acad Sci U S A (1982) 4.70
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology (1981) 4.68
Isolation and transmission of human retrovirus (human t-cell leukemia virus). Science (1983) 4.67
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature (1990) 4.47
Seroepidemiology of HTLV-III antibody in Danish homosexual men: prevalence, transmission, and disease outcome. Br Med J (Clin Res Ed) (1984) 4.39
Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sézary T-cell leukaemia. Nature (1981) 4.38
Differential expression of the amv gene in human hematopoietic cells. Proc Natl Acad Sci U S A (1982) 4.37
Molecular cloning and characterization of the HTLV-III virus associated with AIDS. Nature (1984) 4.35
Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature (1987) 4.35
Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus. Science (1985) 4.31
Expanded HIV-1 cellular tropism by phenotypic mixing with murine endogenous retroviruses. Science (1990) 4.28
Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA (1985) 4.26
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes. Proc Natl Acad Sci U S A (1981) 4.24
Infectious mutants of HTLV-III with changes in the 3' region and markedly reduced cytopathic effects. Science (1986) 4.17
Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology (1983) 4.11
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol (2002) 4.11
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. J Virol (1989) 4.07
Biochemical and immunological analysis of human immunodeficiency virus gag gene products p17 and p24. J Virol (1988) 4.06
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
Four novel U RNAs are encoded by a herpesvirus. Cell (1988) 3.86
Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science (1983) 3.82
Biologically diverse molecular variants within a single HIV-1 isolate. Nature (1988) 3.80
Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet (1984) 3.77
Chromosomal sublocalization of human c-myb and c-fes cellular onc genes. Nature (1983) 3.77
Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan. Proc Natl Acad Sci U S A (1982) 3.75
Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA (1986) 3.74